SRZN a Penny biotech LONGSRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has
advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down
before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful
for liver metabolic disorders from a genetic basis.
SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up
60% of its price while breaking out through the anchored VWAP lines and the volume profile.
The far greater market is the former.
It is priced at 90 or more off it's all-time high of about $160. IF it picks up hype from the
last clinical trial getting a report and a calendared review by the, SRZN could reach for that
all time high. This is speculative and risky as are most biotechnology penny stocks. They are
trading news and potential not current net revenues. A small position with room in the stop
loss for the average range and volatility is best. This is a typical high risk higher potential
reward type of trade.
